An integrated virtual screening approach for VEGFR-2 inhibitors

Journal of Chemical Information and Modeling

Volumn 53, Issue 12, 2013, Pages 3163-3177

  Zhang, Yanmin ^a   Yang, Shangyan ^a   Jiao, Yu ^a   Liu, Haichun ^a   Yuan, Haoliang ^a   Lu, Shuai ^a   Ran, Ting ^a   Yao, Sihui ^a   Ke, Zhipeng ^a   Xu, Jinxing ^a   Xiong, Xiao ^a   Chen, Yadong ^a   Lu, Tao ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

PHARMACODYNAMICS;

COMPREHENSIVE COMPARISONS; INTEGRATED APPROACH; MOLECULAR DOCKING; PHARMACOPHORES; SCORING FUNCTIONS; TWO-LAYER; VEGFR-2; VIRTUAL SCREENING;

MOLECULAR MODELING;

ANGIOGENESIS INHIBITOR; LIGAND; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2, HUMAN; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2, HUMAN; VASCULOTROPIN RECEPTOR 2;

ARTICLE; CHEMISTRY; COMPUTER INTERFACE; COMPUTER PROGRAM; DRUG ANTAGONISM; DRUG DEVELOPMENT; HIGH THROUGHPUT SCREENING; HUMAN; MOLECULAR DOCKING; MOLECULAR LIBRARY; PROBABILITY; PROTEIN BINDING; PROTEIN DATABASE; STRUCTURE ACTIVITY RELATION;

ANGIOGENESIS INHIBITORS; DATABASES, PROTEIN; DRUG DISCOVERY; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; LIGANDS; MOLECULAR DOCKING SIMULATION; PROBABILITY; PROTEIN BINDING; SMALL MOLECULE LIBRARIES; SOFTWARE; STRUCTURE-ACTIVITY RELATIONSHIP; USER-COMPUTER INTERFACE; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 84896528981     PISSN: 15499596     EISSN: 1549960X     Source Type: Journal    
DOI: 10.1021/ci400429g     Document Type: Article

References (56)

1. Kiselyov, A.; Balakin, K. V.; Tkachenko, S. E. VEGF/VEGFR signalling as a target for inhibiting angiogenesis Expert Opin. Investig. Drugs. 2007, 16, 83-107
2. Musumeci, F.; Radi, M.; Brullo, C.; Schenone, S. Vascular Endothelial Growth Factor (VEGF) Receptors: Drugs and New Inhibitors J. Med. Chem. 2012, 55, 10797-10822
3. Ivy, S. P.; Wick, J. Y.; Kaufman, B. M. An overview of small-molecule inhibitors of VEGFR signaling Nat. Rev. Clin. Oncol. 2009, 6, 569-579
4. Huang, L.; Huang, Z.; Bai, Z.; Xie, R.; Sun, L.; Lin, K. Development and strategies of VEGFR-2/KDR inhibitors Future Med. Chem. 2012, 4, 1839-1852
5. Boyer, S. J. Small molecule inhibitors of KDR (VEGFR-2) kinase: an overview of structure activity relationships Curr. Top. Med. Chem. 2002, 2, 973-1000
6. Zhang, Y.; Liu, H.; Jiao, Y.; Yuan, H.; Wang, F.; Lu, S.; Yao, S.; Ke, Z.; Tai, W.; Jiang, Y. De novo design of N-(pyridin-4-ylmethyl) aniline derivatives as KDR inhibitors: 3D-QSAR, molecular fragment replacement, protein-ligand interaction fingerprint, and ADMET prediction Mol. Divers. 2012, 16, 787-802
7. Wenzell, C. M. HOPA News 2013, 1.
8. DiGiulio, S. FDA Approves Stivarga for Advanced GIST Oncology Times 2013, 35 (6) 12
9. Bajorath, J. Integration of virtual and high-throughput screening Nat. Rev. Drug Discovery. 2002, 1, 882-894
10. Schneider, G. Virtual screening: an endless staircase? Nat Rev. Drug Discovery 2010, 9, 273-276
11. Tian, S.; Sun, H.; Li, Y.; Pan, P.; Li, D.; Hou, T. Development and evaluation of an integrated virtual screening strategy by combining molecular docking and pharmacophore searching based on multiple protein structures J. Chem. Inf. Model. 2013, 53, 2743-2756
12. Hou, T.; Xu, X. Recent development and application of virtual screening in drug discovery: an overview Curr. Pharm. Des 2004, 10, 1011-1033
13. Walters, W. P.; Stahl, M. T.; Murcko, M. A. Virtual screening - an overview Drug Discov. Today 1998, 3, 160-178
14. Drwal, M. N.; Griffith, R. Combination of ligand- and structure-based methods in virtual screening Drug Discovery Today: Technol. 2013, 10, 395
15. Hein, M.; Zilian, D.; Sotriffer, C. A. Docking compared to 3D-pharmacophores: the scoring function challenge Drug Discovery Today: Technol. 2011, 7, e229-e236
16. Johnson, M. A.; Maggiora, G. M., Concepts and applications of molecular similarity; Wiley: New York, 1990; Vol. 8.
17. Baringhaus, K.-H.; Hessler, G. Fast similarity searching and screening hit analysis Drug Discovery Today: Technol 2004, 1, 197-202
18. Hu, G.; Kuang, G.; Xiao, W.; Li, W.; Liu, G.; Tang, Y. Performance evaluation of 2D fingerprint and 3D shape similarity methods in virtual screening J. Chem. Inf. Model. 2012, 52, 1103-1113
19. Planesas, J. M.; Claramunt, R. M.; Teixidó, J.; Borrell, J. I.; Pérez-Nueno, V. I. Improving VEGFR-2 docking-based screening by pharmacophore postfiltering and similarity search postprocessing J. Chem. Inf. Model. 2011, 51, 777-787
20. Eckert, H.; Bajorath, J. Molecular similarity analysis in virtual screening: foundations, limitations and novel approaches Drug Discovery Today 2007, 12, 225-233
21. Yang, S.-Y. Pharmacophore modeling and applications in drug discovery: challenges and recent advances Drug Discovery Today 2010, 15, 444-450
22. Zou, J.; Xie, H.-Z.; Yang, S.-Y.; Chen, J.-J.; Ren, J.-X.; Wei, Y.-Q. Towards more accurate pharmacophore modeling: Multicomplex-based comprehensive pharmacophore map and most-frequent-feature pharmacophore model of CDK2 J. Mol. Graph. Model. 2008, 27, 430
23. Wilson, G. L.; Lill, M. A. Integrating structure-based and ligand-based approaches for computational drug design Future Med. Chem. 2011, 3, 735-750
24. Tanrikulu, Y.; Krüger, B.; Proschak, E. The holistic integration of virtual screening in drug discovery Drug Discovery Today 2013, 18, 315-416
25. Krüger, D. M.; Evers, A. Comparison of Structure-and Ligand-Based Virtual Screening Protocols Considering Hit List Complementarity and Enrichment Factors ChemMedChem 2010, 5, 148-158
26. Mysinger, M. M.; Carchia, M.; Irwin, J. J.; Shoichet, B. K. Directory of useful decoys, enhanced (DUD-E): better ligands and decoys for better benchmarking J. Med. Chem. 2012, 55, 6582-6594
27. Berman, H. M.; Battistuz, T.; Bhat, T.; Bluhm, W. F.; Bourne, P. E.; Burkhardt, K.; Feng, Z.; Gilliland, G. L.; Iype, L.; Jain, S. The protein data bank Acta Crystallogr., Sect D 2002, 58, 899-907
28. Kaminski, G. A.; Friesner, R. A.; Tirado-Rives, J.; Jorgensen, W. L. Evaluation and reparametrization of the OPLS-AA force field for proteins via comparison with accurate quantum chemical calculations on peptides J. Phys. Chem. B 2001, 105, 6474-6487
29. Good, A. C.; Oprea, T. I. Optimization of CAMD techniques 3. Virtual screening enrichment studies: a help or hindrance in tool selection? J. Comput. Aided Mol. Des. 2008, 22, 169-178
30. Cross, J. B.; Thompson, D. C.; Rai, B. K.; Baber, J. C.; Fan, K. Y.; Hu, Y.; Humblet, C. Comparison of several molecular docking programs: pose prediction and virtual screening accuracy J. Chem. Inf. Model. 2009, 49, 1455-1474
31. Labute, P. Protonate3D: assignment of ionization states and hydrogen coordinates to macromolecular structures Proteins 2009, 75, 187-205
32. Konagurthu, A. S.; Whisstock, J. C.; Stuckey, P. J.; Lesk, A. M. MUSTANG: a multiple structural alignment algorithm Proteins 2006, 64, 559-574
33. Wu, G.; Robertson, D. H.; Brooks, C. L.; Vieth, M. Detailed analysis of grid-based molecular docking: A case study of CDOCKER-A CHARMm-based MD docking algorithm J. Comput. Chem. 2003, 24, 1549-1562
34. Mackey, M. D.; Melville, J. L. Better than random? The chemotype enrichment problem J. Chem. Inf. Model. 2009, 49, 1154-1162
35. Bharatham, N.; Bharatham, K.; Lee, K. W. Pharmacophore identification and virtual screening for methionyl-tRNA synthetase inhibitors J. Mol. Graph. Model. 2007, 25, 813-823
36. Verdonk, M. L.; Cole, J. C.; Hartshorn, M. J.; Murray, C. W.; Taylor, R. D. Improved protein-ligand docking using GOLD Proteins 2003, 52, 609-623
37. Cheng, F.; Wang, Q.; Chen, M.; Quiocho, F. A.; Ma, J. Molecular docking study of the interactions between the thioesterase domain of human fatty acid synthase and its ligands Proteins 2008, 70, 1228-1234
38. Wolber, G.; Langer, T. LigandScout: 3-D pharmacophores derived from protein-bound ligands and their use as virtual screening filters J. Chem. Inf. Model. 2005, 45, 160-169
39. Jacobsson, M.; Lidén, P.; Stjernschantz, E.; Boström, H.; Norinder, U. Improving structure-based virtual screening by multivariate analysis of scoring data J. Med. Chem. 2003, 46, 5781-5789
40. Hecker, E. A.; Duraiswami, C.; Andrea, T. A.; Diller, D. J. Use of catalyst pharmacophore models for screening of large combinatorial libraries J. Chem. Inf. Comput. Sci. 2002, 42, 1204-1211
41. Diller, D. J.; Li, R. Kinases, homology models, and high throughput docking J. Med. Chem. 2003, 46, 4638-4647
42. Hamza, A.; Wei, N.-N.; Zhan, C.-G. Ligand-based virtual screening approach using a new scoring function J. Chem. Inf. Model. 2012, 52, 963-974
43. Jain, A. N.; Nicholls, A. Recommendations for evaluation of computational methods J. Comput. Aided Mol. Des. 2008, 22, 133-139
44. Triballeau, N.; Acher, F.; Brabet, I.; Pin, J.-P.; Bertrand, H.-O. Virtual screening workflow development guided by the "receiver operating characteristic" curve approach. Application to high-throughput docking on metabotropic glutamate receptor subtype 4 J. Med. Chem. 2005, 48, 2534-2547
45. Enyedy, I. J.; Egan, W. J. Can we use docking and scoring for hit-to-lead optimization? J. Comput. Aided Mol. Des. 2008, 22, 161-168
46. Miyazaki, Y.; Matsunaga, S.; Tang, J.; Maeda, Y.; Nakano, M.; Philippe, R. J.; Shibahara, M.; Liu, W.; Sato, H.; Wang, L. Novel 4-amino-furo [2, 3- d ] pyrimidines as Tie-2 and VEGFR2 dual inhibitors Bioorg. Med. Chem. Lett. 2005, 15, 2203-2207
47. Harmange, J.-C.; Weiss, M. M.; Germain, J.; Polverino, A. J.; Borg, G.; Bready, J.; Chen, D.; Choquette, D.; Coxon, A.; DeMelfi, T. Naphthamides as Novel and Potent Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors: Design, Synthesis, and Evaluation J. Med. Chem. 2008, 51, 1649-1667
48. Cee, V. J.; Cheng, A. C.; Romero, K.; Bellon, S.; Mohr, C.; Whittington, D. A.; Bak, A.; Bready, J.; Caenepeel, S.; Coxon, A. Pyridyl-pyrimidine benzimidazole derivatives as potent, selective, and orally bioavailable inhibitors of Tie-2 kinase Bioorg. Med. Chem. Lett. 2009, 19, 424-427
49. He, G.; Qiu, M.; Li, R.; Ouyang, L.; Wu, F.; Song, X.; Cheng, L.; Xiang, M.; Yu, L. Multicomplex-Based Pharmacophore-Guided 3D-QSAR Studies of N-Substituted 2′-(Aminoaryl) Benzothiazoles as Aurora-A Inhibitors Chem. Biol. Drug. Des. 2012, 79, 960-971
50. Urniaz, R. D.; Jozwiak, K. X-ray Crystallographic Structures as a Source of Ligand Alignment in 3D-QSAR J. Chem. Inf. Model. 2013, 53, 1406-1414
51. Kinnings, S. L.; Jackson, R. M. LigMatch: a multiple structure-based ligand matching method for 3D virtual screening J. Chem. Inf. Model. 2009, 49, 2056-66
52. Cheeseright, T. J.; Mackey, M. D.; Melville, J. L.; Vinter, J. G. FieldScreen: virtual screening using molecular fields. Application to the DUD data set J. Chem. Inf. Model. 2008, 48, 2108-2117
53. Pérez-Nueno, V. I.; Ritchie, D. W. Using consensus-shape clustering to identify promiscuous ligands and protein targets and to choose the right query for shape-based virtual screening J. Chem. Inf. Model. 2011, 51, 1233-1248
54. Jahn, A.; Hinselmann, G.; Fechner, N.; Zell, A. Optimal assignment methods for ligand-based virtual screening J. Cheminf. 2009, 1, 14
55. Vainio, M. J.; Puranen, J. S.; Johnson, M. S. ShaEP: molecular overlay based on shape and electrostatic potential J. Chem. Inf. Model. 2009, 49, 492-502
56. Kirchmair, J.; Distinto, S.; Markt, P.; Schuster, D.; Spitzer, G. M.; Liedl, K. R.; Wolber, G. How to optimize shape-based virtual screening: choosing the right query and including chemical information J. Chem. Inf. Model. 2009, 49, 678-692